China Health Group Limited (Carrying on business in Hong Kong as CHG HS Limited) (Incorporated in Bermuda with limited liability) (Stock Code: 673) released its unaudited condensed consolidated interim financial statements for the six months ended 30 September 2025.

The company recorded revenue of approximately HK$19.6 million, up from about HK$18.7 million in the same period last year. Gross profit came in at roughly HK$1.8 million compared with HK$2.0 million a year earlier. The loss attributable to owners of the company decreased to about HK$10.4 million from HK$17.4 million. Basic and diluted loss per share amounted to HK(2.11) cents, compared to HK(3.59) cents in the previous period.

During the reporting period, the distribution and service in medical equipment and consumables segment contributed around HK$15.6 million revenue—an increase from HK$13.2 million previously—while the hospital operation and management services segment generated around HK$4.1 million, down from HK$5.5 million. The hospital business mainly involved Anping Hospital in Hebei Province, which is undergoing adjustments to its service scope toward rehabilitation and health-management offerings.

As of 30 September 2025, the company held cash and bank balances of approximately HK$63.0 million, with current assets totaling around HK$169.3 million, while net current liabilities stood at around HK$42.5 million. Bank borrowing amounted to about HK$5.5 million. Net liabilities were approximately HK$10.5 million.

In respect of corporate updates, there was a disposal of Jinmei Developments Limited pursuant to a settlement deed concluded in July 2025. In addition, planned acquisitions such as that of 100% equity interest in ProteinT (Tianjin) Diagnostic, Co., Ltd, did not go through as the relevant agreement lapsed. The company also made efforts to recover certain loan and interest receivables through legal means and negotiations.

Separately, on 6 October 2025, the company completed subscriptions of shares and a rights issue, raising net proceeds of around HK$80.9 million. According to disclosures, the proceeds are intended primarily for settling payables, repaying part of a settlement note, and for working capital.

The interim financial statements were approved by the board on 28 November 2025. No interim dividend was proposed for the six months ended 30 September 2025.